Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MAMMALIAN ERAD

Financiado

Cerrado

EXPANDING THE KNOWLEDGE ON MAMMALIAN ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATIO...

EXPANDING THE KNOWLEDGE ON MAMMALIAN ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION ERAD The misfolded, unfolded or unassembled proteins in the Endoplasmic Reticulum (ER) are degraded by the Protein Quality Control Mechanism named as ER-associated degradation (ERAD). In addition to its safeguard role, ERAD can regulat... ver más

31/03/2013

EGE UNIVERSITESI

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

EGE UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EGE UNIVERSITESI

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RIBORESCUEPHAGY How does autophagy rescue stalled ribosomes? 2M€ Cerrado

BFU2008-04285 MECANISMOS MOLECULARES IMPLICADOS EN EL CO NTROL DE CALIDAD... 169K€ Cerrado

ERAD_SELMA Mechanisms of protein translocation in ER associated protein... 2M€ Cerrado

BFU2015-62721-ERC MECANISMOS DE CONTROL DE LA HOMEOSTASIS DEL RETICULO ENDOPLA... 30K€ Cerrado

RYC-2008-02016 Molecular Mechanism and Regulation of Endoplasmic Reticulum... 192K€ Cerrado

ProteoNE_dynamics Surveillance mechanisms regulating nuclear envelope architec... 2M€ Cerrado

Líder del proyecto

EGE UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The misfolded, unfolded or unassembled proteins in the Endoplasmic Reticulum (ER) are degraded by the Protein Quality Control Mechanism named as ER-associated degradation (ERAD). In addition to its safeguard role, ERAD can regulate physiological processes that occur in the ER, for example degradation of HMG–CoA reductase, the key enzyme of cholesterol synthesis. ERAD is a multistep process, which starts with substrate (unwanted protein) selection followed by ubiquitination, retrotranslocation, deglycosylation and proteasomal degradation. Aberrant ERAD has implications on several diseases, such as cystic fibrosis, a1-antitrypsin (AAT) deficiency, diabetes, neurodegenerative diseases and cancer. The details of ERAD mechanism are very well known through the studies in S.cerevisiae. Although the general scheme of the pathway is similar, ERAD is more complicated and highly regulated in mammals than in yeast. Studies in yeast suggested existence specialized ERAD pathways depending on the feature of the protein. These pathways are: ERAD-C ( for cytoplasmic misfolded domains), ERAD-L (for luminal misfolded regions), ERAD-M (for membrane misfolded regions). So far, this issue has not been studied in mammalian cells. Here, we intend to identify substrate specific differences present in retrotranslocation machineries in mammalian ERAD using four substrates with different structural features. Additionally, the effect of SVIP (the first identified endogenous ERAD inhibitor) on these substrates, the role of Npl4 in gp78-mediated ERAD and possible functional interaction of gp78 and hHrd1 enzymes will be examined. This research will provide the first information on the substrate specific differences of mammalian ERAD, and also the functional interaction between two important ER-resident E3s: gp78 and Hrd1. Our results on substrate specific ERAD mechanism would contribute to the studies on the therapies of diseases such as cystic fibrosis and AAT deficiency.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores